Availability, use, efficacy and safety of bevacizumab in European hereditary haemorrhagic telangiectasia centres

Pernille D. Haahr, Anette D. Kjeldsen, Annette D. Fialla, Anne‐Emmanuelle Fargeton, Alexandre Guilhem, Elisabetta Buscarini, Freya Droege, Guido Manfredi, Hans‐Jurgen Mager, Jean‐Christophe Saurin, Jens Kjeldsen, Josefien Hessels, Marco C. Post, Robert Mandic, Sanne Boerman, Stefan Kasper‐Virchow, Sören Möller, Urban Geisthoff, Sophie Dupuis‐Girod

Open source

DOI: 10.1002/bcp.70273
Published: 2025-09-23
Container: British Journal of Clinical Pharmacology
Publisher: Wiley
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/bcp.70273,
  title = {Availability, use, efficacy and safety of bevacizumab in European hereditary haemorrhagic telangiectasia centres},
  author = {Pernille D. Haahr and Anette D. Kjeldsen and Annette D. Fialla and Anne‐Emmanuelle Fargeton and Alexandre Guilhem and Elisabetta Buscarini and Freya Droege and Guido Manfredi and Hans‐Jurgen Mager and Jean‐Christophe Saurin and Jens Kjeldsen and Josefien Hessels and Marco C. Post and Robert Mandic and Sanne Boerman and Stefan Kasper‐Virchow and Sören Möller and Urban Geisthoff and Sophie Dupuis‐Girod},
  year = {2025},
  journal = {British Journal of Clinical Pharmacology},
  doi = {10.1002/bcp.70273},
  url = {https://doi.org/10.1002/bcp.70273}
}

RIS

TY  - JOUR
TI  - Availability, use, efficacy and safety of bevacizumab in European hereditary haemorrhagic telangiectasia centres
AU  - Pernille D. Haahr
AU  - Anette D. Kjeldsen
AU  - Annette D. Fialla
AU  - Anne‐Emmanuelle Fargeton
AU  - Alexandre Guilhem
AU  - Elisabetta Buscarini
AU  - Freya Droege
AU  - Guido Manfredi
AU  - Hans‐Jurgen Mager
AU  - Jean‐Christophe Saurin
AU  - Jens Kjeldsen
AU  - Josefien Hessels
AU  - Marco C. Post
AU  - Robert Mandic
AU  - Sanne Boerman
AU  - Stefan Kasper‐Virchow
AU  - Sören Möller
AU  - Urban Geisthoff
AU  - Sophie Dupuis‐Girod
PY  - 2025
JO  - British Journal of Clinical Pharmacology
DO  - 10.1002/bcp.70273
UR  - https://doi.org/10.1002/bcp.70273
ER  -

APA

Haahr, P. D., Kjeldsen, A. D., Fialla, A. D., Fargeton, A., Guilhem, A., Buscarini, E., Droege, F., Manfredi, G., Mager, H., Saurin, J., Kjeldsen, J., Hessels, J., Post, M. C., Mandic, R., Boerman, S., Kasper‐Virchow, S., Möller, S., Geisthoff, U., & Dupuis‐Girod, S. (2025). Availability, use, efficacy and safety of bevacizumab in European hereditary haemorrhagic telangiectasia centres. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70273

Source records

crossref · retrieved 2026-09-24T21:36:55.253Z